Progressive supranuclear palsy: diagnosis and management
Practical Neurology, 2021 Treating patients with progressive supranuclear palsy (PSP) is both effective and rewarding. This review aims to share our experience in the proactive management of PSP, considering the patient, the family and the medical context in which the illness ...
J. Rowe, N. Holland, T. Rittman
semanticscholar +1 more source
9.4 T MR microscopy of the substantia nigra with pathological validation in controls and disease
NeuroImage: Clinical, 2017 Background: The anatomy of the substantia nigra on conventional MRI is controversial. Even using histological techniques it is difficult to delineate with certainty from surrounding structures.
LA Massey +12 more
doaj +1 more source
Abnormal resting-state functional connectivity in progressive supranuclear palsy and corticobasal syndrome [PDF]
, 2017 Background: Pathological and MRI-based evidence suggests that multiple brain structures are likely to be involved in functional disconnection between brain areas. Few studies have investigated resting-state functional connectivity (rsFC) in progressive
Berardelli, Alfredo +9 more
core +2 more sources
Distinct Lysosomal Network Protein Profiles in Parkinsonian Syndrome Cerebrospinal Fluid. [PDF]
, 2016 BackgroundClinical diagnosis of parkinsonian syndromes like Parkinson's disease (PD), corticobasal degeneration (CBD) and progressive supranuclear palsy (PSP) is hampered by overlapping symptomatology and lack of diagnostic biomarkers, and definitive ...
Boman, Andrea +8 more
core +1 more source
Clinical progression of progressive supranuclear palsy: impact of trials bias and phenotype variants
Brain Communications, 2021 Progressive supranuclear palsy causes diverse clinical presentations, including classical Richardson’s syndrome and several variant phenotypes. Clinical trials of disease-modifying therapies have recently been completed, with more planned for the next 2 ...
D. Street +7 more
semanticscholar +1 more source
Plasma metabolite biomarkers for multiple system atrophy and progressive supranuclear palsy.
PLoS ONE, 2019 Radiological biomarkers have been reported for multiple system atrophy and progressive supranuclear palsy, but serum/plasma biomarkers for each disorder have not been established.
Akio Mori +10 more
doaj +1 more source
A longitudinal study of motor, oculomotor and cognitive function in progressive supranuclear palsy.
PLoS ONE, 2013 ObjectiveWe studied the annual change in measures of motor, oculomotor and cognitive function in progressive supranuclear palsy. This had twin objectives, to assess the potential for clinical parameters to monitor disease progression in clinical trials ...
Boyd C P Ghosh +2 more
doaj +1 more source
Cell Death and Disease, 2020 Tau aggregates propagate in brain cells and transmit to neighboring cells as well as anatomically connected brain regions by prion-like mechanisms. Soluble tau aggregates (tau oligomers) are the most toxic species that initiate neurodegeneration in ...
Nicha Puangmalai +9 more
semanticscholar +1 more source
Brainstem Biomarkers of Clinical Variant and Pathology in Progressive Supranuclear Palsy
Movement Disorders, 2021 Magnetic resonance brainstem measurements are useful structural biomarkers in the Richardson's syndrome variant of progressive supranuclear palsy (PSP). However, it is unclear how these biomarkers differ across the phenotypic spectrum of PSP and how they
Rosalie M. Grijalva +14 more
semanticscholar +1 more source
Comparison of gait in progressive supranuclear palsy, Parkinson’s disease and healthy older adults
BMC Neurology, 2012 Background Progressive supranuclear palsy and Parkinson’s disease have characteristic clinical and neuropathologic profiles, but also share overlapping clinical features. This study aimed to analyze the gait of people with progressive supranuclear palsy (
Egerton Thorlene +2 more
doaj +1 more source